Protease inhibitor plasma concentrations associate with COVID-19 infection

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Protease inhibitor plasma concentrations associate with COVID-19 infection. / Medjeral-Thomas, Nicholas R; Troldborg, Anne; Hansen, Annette G; Pihl, Rasmus; Clarke, Candice L; Peters, James E; Thomas, David C; Willicombe, Michelle; Palarasah, Yaseelan; Botto, Marina; Pickering, Matthew C; Thiel, Steffen.

In: Oxford open immunology, Vol. 2, No. 1, 07.07.2021, p. iqab014.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Medjeral-Thomas, NR, Troldborg, A, Hansen, AG, Pihl, R, Clarke, CL, Peters, JE, Thomas, DC, Willicombe, M, Palarasah, Y, Botto, M, Pickering, MC & Thiel, S 2021, 'Protease inhibitor plasma concentrations associate with COVID-19 infection', Oxford open immunology, vol. 2, no. 1, pp. iqab014. https://doi.org/10.1093/oxfimm/iqab014

APA

Medjeral-Thomas, N. R., Troldborg, A., Hansen, A. G., Pihl, R., Clarke, C. L., Peters, J. E., Thomas, D. C., Willicombe, M., Palarasah, Y., Botto, M., Pickering, M. C., & Thiel, S. (2021). Protease inhibitor plasma concentrations associate with COVID-19 infection. Oxford open immunology, 2(1), iqab014. https://doi.org/10.1093/oxfimm/iqab014

CBE

Medjeral-Thomas NR, Troldborg A, Hansen AG, Pihl R, Clarke CL, Peters JE, Thomas DC, Willicombe M, Palarasah Y, Botto M, Pickering MC, Thiel S. 2021. Protease inhibitor plasma concentrations associate with COVID-19 infection. Oxford open immunology. 2(1):iqab014. https://doi.org/10.1093/oxfimm/iqab014

MLA

Medjeral-Thomas, Nicholas R et al. "Protease inhibitor plasma concentrations associate with COVID-19 infection". Oxford open immunology. 2021, 2(1). iqab014. https://doi.org/10.1093/oxfimm/iqab014

Vancouver

Medjeral-Thomas NR, Troldborg A, Hansen AG, Pihl R, Clarke CL, Peters JE et al. Protease inhibitor plasma concentrations associate with COVID-19 infection. Oxford open immunology. 2021 Jul 7;2(1):iqab014. https://doi.org/10.1093/oxfimm/iqab014

Author

Medjeral-Thomas, Nicholas R ; Troldborg, Anne ; Hansen, Annette G ; Pihl, Rasmus ; Clarke, Candice L ; Peters, James E ; Thomas, David C ; Willicombe, Michelle ; Palarasah, Yaseelan ; Botto, Marina ; Pickering, Matthew C ; Thiel, Steffen. / Protease inhibitor plasma concentrations associate with COVID-19 infection. In: Oxford open immunology. 2021 ; Vol. 2, No. 1. pp. iqab014.

Bibtex

@article{7e5676a3d3e04f9e9f6532bffbaf5487,
title = "Protease inhibitor plasma concentrations associate with COVID-19 infection",
abstract = "Protease inhibitors influence a range of innate immunity and inflammatory pathways. We quantified plasma concentrations of key anti-inflammatory protease inhibitors in chronic haemodialysis patients with coronavirus disease 2019 (COVID-19). The samples were collected early in the disease course to determine whether plasma protease inhibitor levels associated with the presence and severity of COVID-19. We used antibody-based immunoassays to measure plasma concentrations of C1 esterase inhibitor, alpha2-macroglobulin, antithrombin and inter-alpha-inhibitor heavy chain 4 (ITIH4) in 100 serial samples from 27 haemodialysis patients with COVID-19. ITIH4 was tested in two assays, one measuring intact ITIH4 and another also detecting any fragmented ITIH4 (total ITIH4). Control cohorts were 32 haemodialysis patients without COVID-19 and 32 healthy controls. We compared protease inhibitor concentration based on current and future COVID-19 severity and with C-reactive protein. Results were adjusted for repeated measures and multiple comparisons. Analysis of all available samples demonstrated lower plasma C1 esterase inhibitor and α2M and higher total ITIH4 in COVID-19 compared with dialysis controls. These differences were also seen in the first sample collected after COVID-19 diagnosis, a median of 4 days from diagnostic swab. Plasma ITIH4 levels were higher in severe than the non-severe COVID-19. Serum C-reactive protein correlated positively with plasma levels of antithrombin, intact ITIH4 and total ITIH4. In conclusion, plasma protease inhibitor concentrations are altered in COVID-19.",
author = "Medjeral-Thomas, {Nicholas R} and Anne Troldborg and Hansen, {Annette G} and Rasmus Pihl and Clarke, {Candice L} and Peters, {James E} and Thomas, {David C} and Michelle Willicombe and Yaseelan Palarasah and Marina Botto and Pickering, {Matthew C} and Steffen Thiel",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press.",
year = "2021",
month = jul,
day = "7",
doi = "10.1093/oxfimm/iqab014",
language = "English",
volume = "2",
pages = "iqab014",
journal = "Oxford open immunology",
issn = "2633-6960",
number = "1",

}

RIS

TY - JOUR

T1 - Protease inhibitor plasma concentrations associate with COVID-19 infection

AU - Medjeral-Thomas, Nicholas R

AU - Troldborg, Anne

AU - Hansen, Annette G

AU - Pihl, Rasmus

AU - Clarke, Candice L

AU - Peters, James E

AU - Thomas, David C

AU - Willicombe, Michelle

AU - Palarasah, Yaseelan

AU - Botto, Marina

AU - Pickering, Matthew C

AU - Thiel, Steffen

N1 - © The Author(s) 2021. Published by Oxford University Press.

PY - 2021/7/7

Y1 - 2021/7/7

N2 - Protease inhibitors influence a range of innate immunity and inflammatory pathways. We quantified plasma concentrations of key anti-inflammatory protease inhibitors in chronic haemodialysis patients with coronavirus disease 2019 (COVID-19). The samples were collected early in the disease course to determine whether plasma protease inhibitor levels associated with the presence and severity of COVID-19. We used antibody-based immunoassays to measure plasma concentrations of C1 esterase inhibitor, alpha2-macroglobulin, antithrombin and inter-alpha-inhibitor heavy chain 4 (ITIH4) in 100 serial samples from 27 haemodialysis patients with COVID-19. ITIH4 was tested in two assays, one measuring intact ITIH4 and another also detecting any fragmented ITIH4 (total ITIH4). Control cohorts were 32 haemodialysis patients without COVID-19 and 32 healthy controls. We compared protease inhibitor concentration based on current and future COVID-19 severity and with C-reactive protein. Results were adjusted for repeated measures and multiple comparisons. Analysis of all available samples demonstrated lower plasma C1 esterase inhibitor and α2M and higher total ITIH4 in COVID-19 compared with dialysis controls. These differences were also seen in the first sample collected after COVID-19 diagnosis, a median of 4 days from diagnostic swab. Plasma ITIH4 levels were higher in severe than the non-severe COVID-19. Serum C-reactive protein correlated positively with plasma levels of antithrombin, intact ITIH4 and total ITIH4. In conclusion, plasma protease inhibitor concentrations are altered in COVID-19.

AB - Protease inhibitors influence a range of innate immunity and inflammatory pathways. We quantified plasma concentrations of key anti-inflammatory protease inhibitors in chronic haemodialysis patients with coronavirus disease 2019 (COVID-19). The samples were collected early in the disease course to determine whether plasma protease inhibitor levels associated with the presence and severity of COVID-19. We used antibody-based immunoassays to measure plasma concentrations of C1 esterase inhibitor, alpha2-macroglobulin, antithrombin and inter-alpha-inhibitor heavy chain 4 (ITIH4) in 100 serial samples from 27 haemodialysis patients with COVID-19. ITIH4 was tested in two assays, one measuring intact ITIH4 and another also detecting any fragmented ITIH4 (total ITIH4). Control cohorts were 32 haemodialysis patients without COVID-19 and 32 healthy controls. We compared protease inhibitor concentration based on current and future COVID-19 severity and with C-reactive protein. Results were adjusted for repeated measures and multiple comparisons. Analysis of all available samples demonstrated lower plasma C1 esterase inhibitor and α2M and higher total ITIH4 in COVID-19 compared with dialysis controls. These differences were also seen in the first sample collected after COVID-19 diagnosis, a median of 4 days from diagnostic swab. Plasma ITIH4 levels were higher in severe than the non-severe COVID-19. Serum C-reactive protein correlated positively with plasma levels of antithrombin, intact ITIH4 and total ITIH4. In conclusion, plasma protease inhibitor concentrations are altered in COVID-19.

U2 - 10.1093/oxfimm/iqab014

DO - 10.1093/oxfimm/iqab014

M3 - Journal article

C2 - 34458849

VL - 2

SP - iqab014

JO - Oxford open immunology

JF - Oxford open immunology

SN - 2633-6960

IS - 1

ER -